Press Releases

Results Found (130)
November 12, 2008
BIOLINERX AND YISSUM SIGN A LICENSING AGREEMENT FOR THE DEVELOPMENT OF A...

Yissum the Technology Transfer Company of the Hebrew University of Jerusalem, and BioLineRx , a clinical stage drug development company, today announced that they have signed a worldwide exclusive license agreement for BioLineRx to develop and...

October 2, 2008
YISSUM ANNOUNCES A NOVEL METHOD FOR SWIFT AND ROBUST PATTERN RECOGNITION

Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, introduced today a novel method for real time, automatic, generic and robust pattern matching. The novel algorithm, developed by Professor Michael Werman and Ofir...

September 29, 2008
New YISSUM’S TECHNOLOGY TRANSFER INTERNATIONAL INTERNSHIP PROGRAM OPENING...

An international internship program has been running at Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, for the past two years. The program aims both to expand international relationships that will encourage new...

May 27, 2008
YISSUM INTRODUCES NOVEL DEVICE FOR IMPROVED SALIVA BASED MEDICAL DIAGNOSTICS

Technology Presented at ILSI BioMed Israel 2008 conference

March 11, 2008
YISSUM ANNOUNCES THE LAUNCH OF THE HEBREW UNIVERSITY’S GENETIC RESOURCE...

The Hebrew University Genetic Resource (HUGR) platform includes 15,000 DNA samples of Ashkenazi Jews

February 27, 2008
YISSUM ANNOUNCES THE DISCOVERY OF A NOVEL SMALL MOLECULE WITH POTENT...

cientists from the School of Pharmacy at the Hebrew University of Jerusalem discovered a novel orally available drug that prevents metastasis formation in various types of cancers.

February 12, 2008
MORRIA BIOPHARMACEUTICALS PLC ANNOUNCES PRELIMINARY SAFETY AND TOLERABILITY...

Yissum spin-off Morria Biopharmaceuticals, a biopharmaceutical company focused on the development of novel anti- inflammatory drugs, announced the preliminary safety results from its Phase I safety and tolerability study of MRX-4 in 16 patients...

January 8, 2008
YISSUM AND EUCALYPTUS SIGN LICENSING AGREEMENT FOR THE DEVELOPMENT OF A...

Molecule is an antioxidant that overcomes the blood-brain barrier

December 25, 2007
YISSUM SPINS-OFF NANOLYMF TO ADVANCE BREAKTHROUGH LIVER-BYPASSING ORAL DRUG...

Yissum announced the formation of Nanolymf, a biotechnology start up company dedicated to advancing a nanotechnology controlled release drug delivery platform that increases the bioavailability of orally administrated lipophilic drugs.

December 25, 2007
YISSUM LICENSES ANTI-CANCER COMPOUND BL-4060 TO BIOLINERX

Yissum and BioLineRx signed a worldwide exclusive license agreement for the development and commercialization of BL-4060, a small molecule drug candidate for the treatment of cancer.

November 6, 2007
BELGIAN CO LICENSES HEBREW U BIODEGRADABLE PLASTIC

Yissum Technology Transfer Company of the Hebrew University of Jerusalem has signed a new licensing agreement with a Belgian holding company for the commercialization of a new clean technology developed at the university.

October 31, 2007
YISSUM PRESENTS AT WATEC 2007 A NEW ENVIRONMENTALLY-FRIENDLY METHOD FOR THE...